gefitinib has been researched along with Cell Transformation, Neoplastic in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 17 (38.64) | 29.6817 |
| 2010's | 25 (56.82) | 24.3611 |
| 2020's | 2 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, YS; Liu, J; Peng, Y; Xia, L; Yang, ZZ | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Favre, L; Helissey, C; Lamboley, JL; Mamou, E; Nguyen, AT | 1 |
| Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wu, J; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L | 1 |
| Fan, Y; Gong, L; Huang, Z; Xu, Y | 1 |
| Fujita, N; Inase, N; Katayama, R; Nishio, M; Uchibori, K | 1 |
| Chai, Y; Wu, Y; Yao, Y; Zhu, Z | 1 |
| Cunha, SI; Jia, M; Souchelnytskyi, S | 1 |
| Amato, M; D'Angelillo, RM; Fiore, M; Perrone, G; Ramella, S; Righi, D; Trecca, P; Trodella, L | 1 |
| Ding, JY; Gao, J; Jiang, JH; Jin, C; Li, HR | 1 |
| Deng, XB; Jin, ZR; Li, XQ; Liu, QZ; Liu, Y; Ma, L; Miao, XB; Sun, DX; Testa, JR; Wu, Y; Xiao, GH; Yao, KT; Zhang, G | 1 |
| Takeuchi, S; Yano, S | 1 |
| Chou, YH; Hsieh, MS; Hua, SF; Jhuang, JY | 1 |
| Al-Ejeh, F; Bessette, DC; Chenevix-Trench, G; Cocciardi, S; Grimmond, SM; Khanna, KK; Lakhani, SR; McCart-Reed, A; Quinn, MC; Saunus, JM; Seidens, T; Shi, W; Simpson, PT; Tilch, E; Waddell, N; Wiegmans, AP | 1 |
| Choe, J; Han, M; Jeoung, D; Kim, H; Kim, Y; Kim, YM; Lee, H; Lee, YS; Park, D | 1 |
| Chen, G; Gao, Y; Huang, C; Lu, Z; Shi, L; Song, Z; Wang, B; Wang, Y; Xu, D; Zhang, H; Zhang, W; Zhang, Y; Zhuang, N | 1 |
| Ellison, K; Hirsch, FR; Kim, J; Mitsudomi, T; Murakami, I; Rivard, CJ; Suda, K; Yu, H | 1 |
| Peng, H; Xia, L; Xiaoli, Z; Zhiqiang, L | 1 |
| Katayama, H; Kishino, D; Kiura, K; Kuyama, S; Ohashi, K; Okada, T; Sato, K; Takigawa, N; Tanimoto, M | 1 |
| Hirano, S; Ichihara, E; Kiura, K; Kubo, T; Ohashi, K; Osawa, M; Takata, M; Takeda, H; Takigawa, N; Tanimoto, M; Yoshino, T | 1 |
| Durbin, JE; Koromilas, AE; Muller, WJ; Raven, JF; Tremblay, ML; Wang, S; Williams, V | 1 |
| Fujita, Y; Hiroshima, K; Niijima, M; Nishio, K; Saitoh, M; Takiguchi, Y; Tatsumi, K | 1 |
| Alder, H; Cascione, L; Condorelli, G; Croce, CM; Di Leva, G; Engelman, JA; Garofalo, M; Jeon, YJ; Lovat, F; Nephew, KP; Ngankeu, A; Nuovo, G; Ono, M; Rho, JK; Romano, G; Sun, J; Volinia, S | 1 |
| Cheng, H; De Luo, B; Liu, ZG; Ren, Y; Zhang, YF; Zhu, H | 1 |
| Chung, KF; Huang, CD; Huang, TT; Kuo, HP; Lee, KY; Lin, HC; Lin, SM; Lo, YL; Wang, CH | 1 |
| Argyle, DJ; Bergkvist, GT; Cervantes-Arias, A; Muirhead, R; Pang, LY; Yool, DA | 1 |
| Boehm, JS; Butaney, M; Cheung, HW; Du, J; Engelman, JA; Golub, TR; Hahn, WC; He, F; Jänne, PA; Luo, B; Meyerson, M; Root, DE; Sequist, LV; Wang, X; Weir, BA | 1 |
| Boerner, JL; Kuperwasser, C; List, K; Madden, JM; Mueller, KL; Zoratti, GL | 1 |
| Chisholm, JW; Igal, RA; Nashed, M | 1 |
| Bunn, PA; Franklin, W | 1 |
| Arteaga, CL; Ritter, CA | 1 |
| Dufresne, A; Gainet, M; Guardiola, E; Pivot, X | 1 |
| Marmé, D | 1 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Jeng, YM; Lien, HC; Su, MC | 1 |
| Alvarez, JV; Bulmer, SE; Chen, TH; Feng, W; Frank, DA; Greulich, H; Hahn, WC; Jänne, PA; Meyerson, M; Sellers, WR; Zappaterra, M | 1 |
| Greulich, H; Griffin, JD; Jänne, PA; Jiang, J; Meyerson, M; Sellers, WR | 1 |
| Gazdar, AF; Girard, L; Lee, W; Minna, JD; Peyton, M; Ramirez, RD; Sato, M; Shames, DS; Shay, JW; Sunaga, N; Vaughan, MB | 1 |
| Furukawa, M; Greene, MI; Inoue, K; Kawase, I; Kijima, T; Kumagai, T; Nagatomo, I; Ogata, Y; Osaki, T; Saito, Y; Tachibana, I; Takahashi, R; Yamadori, T; Yano, Y; Yoneda, T; Yoshida, M | 1 |
| Cecere, F; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| Antonaci, S; Giannelli, G | 1 |
| Chang, A; Zhang, X | 1 |
| Bissonnette, M; Cerda, S; Cohen, G; Dougherty, U; Fichera, A; Gong, C; Hart, J; Jagadeeswaran, S; Joseph, L; Khare, S; Little, N; Mustafi, R; Sehdev, A; Tallerico, M; Tretiakova, M; Turner, JR; Yuan, W | 1 |
| Becker, JC; Schrama, D; Ugurel, S | 1 |
11 review(s) available for gefitinib and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; Disease Progression; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Quinazolinones; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Signal Transduction | 2019 |
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Molecular Targeted Therapy; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Small Cell Lung Carcinoma | 2014 |
Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Cetuximab; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2002 |
The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2003 |
[Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Cell Transformation, Neoplastic; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Survival Analysis; Treatment Outcome | 2003 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
Predicting the outcome of chemotherapy for lung cancer.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mesoderm; Mutation; Nuclear Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Smoking; Thioredoxins; Treatment Outcome; Y-Box-Binding Protein 1 | 2006 |
Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice.
Topics: Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Differentiation; Cell Transformation, Neoplastic; ErbB Receptors; Gefitinib; Humans; Liver Cirrhosis; Neoplasm Invasiveness; Prognosis; Quinazolines | 2006 |
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Ethnicity; Exons; Female; Gefitinib; Genes, erbB-1; Genes, p53; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Mutagenesis, Insertional; Mutation; Mutation, Missense; Protein Structure, Tertiary; Quinazolines; Randomized Controlled Trials as Topic; Sequence Deletion; Smoking | 2007 |
Strategies to optimize the use of targeted agents for tumor therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cell Transformation, Neoplastic; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Synergism; Gefitinib; Gene Silencing; Humans; Neoplasms; Prognosis; Quinazolines | 2008 |
1 trial(s) available for gefitinib and Cell Transformation, Neoplastic
33 other study(ies) available for gefitinib and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Gastric metastasis and transformation of primary lung adenocarcinoma to small cell cancer after acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors: A case report.
Topics: Adenocarcinoma of Lung; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Stomach Neoplasms | 2021 |
What management for epidermal growth factor receptor-mutated non-small-cell lung cancer, with squamous cell transformation and T790M-acquired resistance mechanisms? A Case report and review of literature.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors | 2022 |
Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Real-Time Polymerase Chain Reaction | 2017 |
A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Cell Transformation, Neoplastic; Cells, Cultured; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors | 2018 |
Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2018 |
Exposure to EGF and 17β‑estradiol irreversibly affects the proliferation and transformation of MCF7 cells but is not sufficient to promote tumor growth in a xenograft mouse model upon withdrawal of exposure.
Topics: Animals; Benzamides; Carcinogenesis; Cell Proliferation; Cell Transformation, Neoplastic; Dioxoles; Epidermal Growth Factor; Estradiol; Female; Gefitinib; Humans; MCF-7 Cells; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Phenotype; Quinazolines; Spheroids, Cellular; Tamoxifen; Xenograft Model Antitumor Assays | 2018 |
Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma.
Topics: Adenocarcinoma of Lung; Biomarkers; Biopsy; Cell Transformation, Neoplastic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Middle Aged; Multimodal Imaging; Mutation; Protein Kinase Inhibitors; Radiotherapy; Small Cell Lung Carcinoma | 2019 |
Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cisplatin; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanog Homeobox Protein; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Quinazolines; Side-Population Cells; Signal Transduction; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2015 |
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; Drug Resistance, Neoplasm; ErbB Receptors; Exome; Female; Gefitinib; Gene Expression; Humans; Mice; Mice, Nude; Models, Biological; Mutation; Phosphatidylinositol 3-Kinases; Plasmids; Protein Kinase Inhibitors; Quinazolines; Transfection; Xenograft Model Antitumor Assays | 2015 |
miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neovascularization, Pathologic; Paclitaxel; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2016 |
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop.
Topics: 3' Untranslated Regions; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Movement; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Models, Biological; Neoplastic Stem Cells; NF-kappa B; Quinazolines; RNA Interference; Signal Transduction; Tumor Necrosis Factor alpha-Induced Protein 3 | 2017 |
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
Topics: Adenocarcinoma; Aged; Biomarkers; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
Gefitinib enhances radiotherapeutic effects of
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Protein Transport; Quinazolines; Radiation Tolerance; Radiochemistry; Tissue Distribution | 2017 |
Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.
Topics: Animals; Antineoplastic Agents; Carcinogens, Environmental; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; ErbB Receptors; Female; Gefitinib; Lung; Lung Neoplasms; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Nitrosamines; Pulmonary Fibrosis; Quinazolines; Smoking; Tumor Burden | 2009 |
Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Models, Animal; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Phosphorylation; Promoter Regions, Genetic; Pulmonary Surfactant-Associated Protein C; Quinazolines; Receptor, ErbB-3; Smoking | 2009 |
Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; Disease Progression; Female; Gefitinib; Humans; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT1 Transcription Factor; Transplantation, Heterologous | 2011 |
An early event of EGFR mutation in pleomorphic carcinoma of the lung.
Topics: Antineoplastic Agents; Carcinoma; Cell Transformation, Neoplastic; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2011 |
Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genistein; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Increased activation of fibrocytes in patients with chronic obstructive asthma through an epidermal growth factor receptor-dependent pathway.
Topics: Acetylcysteine; ADAM Proteins; ADAM17 Protein; Adult; Antigens, CD34; Asthma; Blood Cells; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Collagen Type I; ErbB Receptors; Female; Fibroblasts; Follow-Up Studies; Gefitinib; Humans; Hydrogen Peroxide; Leukocyte Common Antigens; Male; Middle Aged; Oxidative Stress; Pulmonary Disease, Chronic Obstructive; Quinazolines; Respiratory Function Tests; Signal Transduction; Stem Cells; Tyrphostins | 2012 |
Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycoproteins; Head and Neck Neoplasms; Humans; Neoplastic Stem Cells; Peptides; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2012 |
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Cell Death; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 22; Epithelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Neurofibromin 1; Nuclear Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; raf Kinases; Shelterin Complex; Signal Transduction; SOS1 Protein; Telomere-Binding Proteins | 2011 |
Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Coculture Techniques; Culture Media, Conditioned; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Gefitinib; Gene Expression; Hepatocyte Growth Factor; Humans; Paracrine Communication; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Triple Negative Breast Neoplasms | 2012 |
Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Stearoyl-CoA Desaturase; TOR Serine-Threonine Kinases | 2012 |
Protein kinase inhibitors: novel tools in cancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Transformation, Neoplastic; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Signal Transduction | 2004 |
Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Sequence Data; Point Mutation; Quinazolines; Sequence Analysis, DNA | 2005 |
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genetic Therapy; Humans; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; STAT3 Transcription Factor; Transfection; Tumor Stem Cell Assay | 2005 |
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Growth Processes; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Interleukin-3; Mice; Mutagenesis, Site-Directed; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transfection | 2005 |
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Topics: Aged; Bronchi; Cell Adhesion; Cell Growth Processes; Cell Transformation, Neoplastic; Dual Specificity Phosphatase 6; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genes, p16; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Oncogenes; Phosphorylation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; STAT3 Transcription Factor; Telomerase; Transfection; Up-Regulation | 2006 |
The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line; Cell Transformation, Neoplastic; DNA; Enzyme Activation; ErbB Receptors; Fibroblasts; Gefitinib; Mice; Mitogen-Activated Protein Kinases; Mutation; Quinazolines; Transfection | 2006 |
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.
Topics: Adenoma; Animals; Azoxymethane; beta Catenin; Carcinogens; Cell Transformation, Neoplastic; Colonic Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, ras; Male; Mice; Mice, Inbred A; Mutation; Quinazolines; Signal Transduction; Up-Regulation | 2007 |